Adaptimmune Therapeutics PLC ADR | Ownership
Companies that own Adaptimmune Therapeutics PLC ADR
Matrix Capital Management Co. LP
14,083,511
14.94%
201,500
4.34%
06/30/2018
Capital Research & Management Co. (World Investors)
7,186,700
7.62%
394,000
0.01%
06/30/2018
Baillie Gifford & Co.
3,033,261
3.22%
467,852
0.02%
06/30/2018
Fidelity Management & Research Co.
1,845,590
1.96%
-403,094
0%
06/30/2018
Wellington Management Co. LLP
1,543,366
1.64%
35,401
0%
06/30/2018
Oracle Investment Management, Inc.
1,393,743
1.48%
63,673
3.53%
06/30/2018
Renaissance Technologies LLC
1,302,107
1.38%
-3,893
0.02%
06/30/2018
Tekla Capital Management LLC
855,468
0.91%
0
0.33%
06/30/2018
Millennium Management LLC
848,855
0.9%
-628,786
0.01%
06/30/2018
Balyasny Asset Management LP
816,284
0.87%
-130,784
0.05%
06/30/2018
| Address |
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
|
|
Employees
|
- |
| Website |
http://adaptimmune.com |
| Updated |
07/08/2019 |
| Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. |
